
John V. Heymach, M.D., Ph.D.
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine


In the News

Study identifies key factor in non-small cell lung cancer resistance and potential therapeutic targets

Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response

Lung cancer targeted therapy hits common HER2 variants across cancers

Poziotinib sustains high response rates against intractable lung cancer mutation

MD Anderson, Spectrum Pharmaceuticals complete poziotinib licensing deal

Size, structure help poziotinib pose threat to deadly exon 20 lung cancer

Chronic stress hormones may promote resistance to EGFR inhibitors in lung cancer patients

Six researchers from MD Anderson elected as AAAS Fellows
Present Title & Affiliation
Primary Appointment
Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
David Bruton, Jr Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
1998 | Stanford University Medical School, Stanford, CA, USA, MD, Medicine |
1996 | Stanford University Medical School, Stanford, CA, USA, PHD, Neuroscience |
1989 | Harvard University, Cambridge, MA, USA, BA, Chemistry |
Postgraduate Training
2000-2003 | Clinical Fellowship, Medical Oncology, Dana-Farber/Partners CancerCare Medical Oncology Fellowship Program, Boston, MA |
1999-2000 | Clinical Residency, Internal Medicine, Brigham and Women′s Hospital, Boston, MA |
1998-1999 | Clinical Internship, Internal Medicine, Brigham and Women′s Hospital, Boston, MA |
Board Certifications
2005 | Medical Oncology, American Board of Internal Medicine |
2002 | Internal Medicine, American Board of Internal Medicine |
Honors & Awards
2020 | Potu N. Rao Award: Excellence in Basic Science Award, The University of Texas MD Anderson Cancer Center |
Selected Publications
Peer-Reviewed Articles
- Cascone T, Heymach JV. Can the Lung Cancer Pie Be Divided into Angiogenic Slices?. Clin Cancer Res 21(23):5188-90, 2015. e-Pub 2015. PMID: 26232370.
- Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-877, 2015. e-Pub 2015. PMID: 26069186.
- Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer 89(1):76-79, 2015. e-Pub 2015. PMID: 25982012.
- Chen L, Heymach JV, Qin FX, Gibbons DL. The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. Oncoimmunology 4(5):e1002731, 2015. e-Pub 2015. PMID: 26155392.
- Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J Cancer 112(7):1199-1205, 2015. e-Pub 2015. PMID: 25756398.
- Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. PLoS One 10(8):e0135962, 2015. e-Pub 2015. PMID: 26313261.
- Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-80, 2015. e-Pub 2015. PMID: 26310908.
- Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second line treatment for patients with advanced non-small cell lung cancer. Ann Oncol 25(10):1941-1948, 2014. e-Pub 2014. PMID: 25057173.
- Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. Cancer Immunol Res 2(9):831-838, 2014. PMID: 25187273.
- Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, Mason KA, Molkentine J, Thames HD, Yoo SS, Heymach JV. A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer. J Thorac Oncol 9(7):965-973, 2014. PMID: 24922006.
- Mehran R, Nilsson M, Khajavi M, Du Z, Cascone T, Wu HK, Cortes A, Xu L, Zurita A, Schier R, Riedel B, El-Zein R, Heymach JV. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res 74(10):2731-2741, 2014. e-Pub 2014. PMID: 24626092.
- Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial. Clin Cancer Res 19(24):6967-6975, 2013. e-Pub 2013. PMID: 24166906.
- Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer. Cancer Discov 3(8):870-879, 2013. e-Pub 2013. PMID: 23715154.
- Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 8(5):658-661, 2013. PMID: 23584298.
- Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-290, 2013. e-Pub 2012. PMID: 23091115.
- Cancer Genome Atlas Research Network, Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, Collisson EA, Cope L, Creighton CJ, Getz G, Herman JG, Johnson BE, Kucherlapati R, Ladanyi M, Maher CA, Robertson G, Sander C, Shen R, Sinha R, Sivachenko A, Thomas RK, Travis WD, Tsao MS, Weinstein JN, Wigle DA, Baylin SB, Govindan R, Meyerson M. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519-525, 2012. e-Pub 2012. PMID: 22960745.
- Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2(9):798-811, 2012. e-Pub 2012. PMID: 22961666.
- Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827-837, 2012. e-Pub 2012. PMID: 22759480.
- Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol 7(8):1211-1217, 2012. PMID: 22617250.
- Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II,Heymach, JV, Powis G. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. J Natl Cancer Inst 104(3):228-239, 2012. e-Pub 2012. PMID: 22247021.
- Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT, Yan S, Dewhirst M, Kunnumakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diet on plasma levels of NF-{kappa}B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) 4(10):1590-1598, 2011. e-Pub 2011. PMID: 21764858.
- Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Res 71(16):5512-5521, 2011. e-Pub 2011. PMID: 21724587.
- de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid Biomarkers Associated with Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept. Clin Cancer Res 17(14):4872-4881, 2011. e-Pub 2011. PMID: 21632852.
- Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Caner. Cancer Discov 1(1):44-53, 2011. e-Pub 2011. PMID: 22586319.
- Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121(4):1313-1328, 2011. e-Pub 2011. PMID: 21436589.
- Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 5(12):1894-1904, 2010. PMID: 21124077.
- Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11(7):619-626, 2010. e-Pub 2010. PMID: 20570559.
- Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-1763, 2010. e-Pub 2010. PMID: 20530716.
- Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18):2616-2627, 2010. e-Pub 2010. PMID: 20154724.
- Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29(20):2938-2949, 2010. e-Pub 2010. PMID: 20208561.
- Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70(6):2171-2179, 2010. e-Pub 2010. PMID: 20215520.
- Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28(2):193-201, 2010. e-Pub 2009. PMID: 19949019.
- Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3):453-459, 2010. e-Pub 2009. PMID: 20008624.
- Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-3609, 2009. e-Pub 2009. PMID: 19447868.
- Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15(10):3484-3494, 2009. e-Pub 2009. PMID: 19447865.
- William WN, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 8(3):213-225, 2009. PMID: 19247304.
- Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407-5415, 2008. e-Pub 2008. PMID: 18936474.
- Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 359(13):1367-1380, 2008. PMID: 18815398.
- Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-Mckay P, Ryan A, Folkman J, Ryeom S, Heymach J,. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 7(2):418-424, 2008. e-Pub 2008. PMID: 18245671.
- Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25(27):4270-4277, 2007. PMID: 17878479.
- Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13(9):2643-2650, 2007. PMID: 17473195.
- Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11(9):3514-3522, 2005. PMID: 15867254.
- Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10(17):5732-5740, 2004. PMID: 15355900.
- Heymach JV, Barres BA. Neurotrophins moving forward. Nature 389(6653):789, 791, 1997. PMID: 9349804.
- Heymach JV, Krüttgen A, Suter U, Shooter EM. The regulated secretion and vectorial targeting of neurotrophins in neuroendocrine and epithelial cells. J Biol Chem 271(41):25430-25437, 1996. PMID: 8810312.
- Heymach JV, Shooter EM. The biosynthesis of neurotrophin heterodimers by transfected mammalian cells. J Biol Chem 270(20):12297-12304, 1995. PMID: 7744882.
- Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach, JV. Increased mobilization of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. e-Pub 2011. PMID: 21673679.
Abstracts
- Elamin Y, Papadimitrakopoulou P, Tong T, Wang J, Lewis J, Rinsurongkawong W, Chu C, Roarty E, Zhang J, Tran H, Rodriguez-Canales J, Parra ER, Behrens C, Kadara H, Wistuba I, Heymach JV. Impact of major co-mutations on the immune contexture and response of KRAS-mutant lung adenocarcinoma to immunotherpy. IASLC 17th World Lung Cancer Conference (WLCC), 2016.
Grant & Contract Support
Title: | Molecular Signatures for Individualizing Lung Cancer Therapy - University of Texas SPORE in Lung Cancer |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Targeting KRAS Mutant Lung Cancers |
Funding Source: | AACR Stand Up to Cancer (SU2C) |
Role: | Sub PI/Leader |
Title: | Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Therapeutic approaches for LKB1-deficient non-small cell lung cancer |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Cancer Center Support Grant |
Funding Source: | NIH/NCI |
Role: | Leader, Lung Cancer Program |
Title: | Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC |
Funding Source: | NIH/NCI |
Role: | Co-Principal Investigator |
Title: | The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Molecular Features Impacting Drug Resistance in Atypical Acquired EGFR Exon 18 and Exon 20 Mutant NSCLC and the Development of Novel Mutant-Selective Inhibitors |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Principal Investigator |
Title: | Developing therapeutic strategies to enhance the effects of immune checkpoint inhibitors in KRAS mutant cancers harboring a concomitant LKB1 mutation |
Funding Source: | MSKCC/The Mark Foundation |
Role: | Site Principal Investigator |
Title: | Targeting selective vulnerabilities in energetic, proteotoxic and oxidative stress in LKB1-deficient KRAS mutant tumors |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Project Leader |
Title: | Therapeutic strategies against EGFR exon 20 mutant lung cancer |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancer and the Development of Novel Mutant-Selective Inhibitors |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Investigation of CD70 targeting as a novel strategy to overcome EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer |
Funding Source: | Emerson Collective |
Role: | Principal Investigator |
Title: | Immunogenomic and Microbiota Evolution from Premalignancy to Lung Cancer |
Funding Source: | AACR Johnson & Johnson Lung Cancer |
Role: | Co-Investigator |
Title: | The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Ziopharm SIV Alliance Research and Development Agreement |
Funding Source: | Ziopharm |
Role: | Principal Investigator |
Title: | Bristol-Myers Squibb Strategic Collaboration Agreement Lung Cancer LONESTAR Randomized phase III trial of local consolidation therapy (LCT) after nivolumab and ipilimumab for immunotherapy-naïve patients with metastatic non-small cell lung cancer |
Funding Source: | Bristol-Myers Squibb |
Role: | Principal Investigator |